ArticleJournal of pharmaceutical health care and sciences2026
Use of Upadacitinib in elderly patients with IBD: a case series.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpadacitinib (UPA) is a selective Janus kinase (JAK) 1 inhibitor that may rapidly induce and maintain a remission of inflammatory bowel disease (IBD) through potent suppression of cytokine signaling. While a pan-JAK inhibitor has been shown to increase the risk of thromboembolic and major cardiovascular events (MACE), especially in elderly patients with rheumatoid arthritis, UPA may potentially be a better therapeutic option for elderly IBD patients owing to its selective effect on JAK1. However, the usefulness of UPA in elderly IBD patients has yet to be well assessed.
methodsTo explore the efficacy and safety of UPA in elderly IBD patients, we conducted a retrospective case series study of patients with ulcerative colitis (UC) and Crohn’s disease (CD) aged over 60 years who received UPA from December 2022 to March 2025. Clinical response and remission rates, incidence of adverse events, and clinical outcomes were analyzed.
resultsA total of 8 patients (5 UC and 3 CD) were included in this study. The rate of clinical response in UC was 40% at week 8, 80% at week 16, and the remission rate was 60% at week 16. One patient with acute severe UC underwent colectomy at week 3 due to resistance to UPA, although the patient had also failed a rescue therapy with infliximab (IFX). In patients with CD, the rate of clinical response and remission at week 12 was 33.3% each. After 52 weeks of treatment, 60% of UC and 66.7% of CD patients had sustained UPA treatment. During the median follow-up time of 14.1 months (95% CI 9.2, 24.4 months), adverse events of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher were identified in two cases. Although one patient with UC discontinued UPA at week 36 due to anemia and liver damage, most adverse events observed were otherwise mild. No serious infections, thromboembolic events, MACE, or malignancies were noted.
conclusionsWhile the small sample size precludes definitive conclusions, this case series suggests that UPA has potential efficacy and relatively acceptable tolerability in elderly patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.